Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin: Rationale and evidences

Expert Review of Clinical Pharmacology

Volumn 9, Issue 3, 2016, Pages 409-418

  Singh, Awadhesh Kumar ^a   Singh, Ritu ^a  

^a GD Hospital and Diabetes Institute   (India)

Author keywords

genitourinary infection; hypoglycemia; insulin; Sodium glucose co transporter 2 inhibitors; type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ERTUGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; IPRAGLIFLOZIN; LUSEOGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SOTAGLIFLOZIN; TOFOGLIFLOZIN; ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2;

BODY WEIGHT; COCHRANE LIBRARY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INSULIN TREATMENT; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; UROGENITAL TRACT INFECTION; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; INSULIN RESISTANCE; METABOLISM; PATHOPHYSIOLOGY;

DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84959562563     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2016.1131121     Document Type: Review

References (40)

1. DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773-795.
2. Turnbull FM, Abraira C, Anderson RJ, et al. Control Group. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52:2288-2298.
3. Hoerger TJ, Segel JE, Gregg EW, et al. Is glycemic control improving in U.S. adults? Diabetes Care. 2008;31:81-86.
4. Buse J. Combining insulin and oral agents. Am J Med. 2000;108(Suppl 6a):23S-32S.
5. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2011;154(2):103-112.
6. Seino Y, Min KW, Takami A, et al. Randomized, doubleblind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia). Diabetes Obes Metab. 2012;14(10):910-917.
7. Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care. 2013;36(9):2497-2503.
8. Rosenstock J, Fonseca VA, Gross JL, et al. Harmony 6 Study Group. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thricedaily prandial insulin lispro. Diabetes Care. 2014;37 (8):2317-2325.
9. Morales J, Merker L. Minimizing hypoglycemia and weight gain with intensive glucose control: potential benefits of a new combination therapy (IDegLira). Adv Ther. 2015;32(5):391-403.
10. Vilsbøll T, Rosenstock J, Yki-Järvinen H, et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:167-177.
11. Hong ES, Khang AR, Yoon JW, et al. Comparison between sitagliptin as add-on therapy to insulin and insulin dose increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes Metab. 2012;14:795-802.
12. Barnett AH, Charbonnel B, Donovan M, et al. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin. 2012;28:513-523.
13. Kothny W, Foley J, Kozlovski P, et al. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15:252-257.
14. Barnett AH, Charbonnel B, Li J, et al. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. Clin Drug Investig. 2013;33:707-717.
15. Yki-Järvinen H, Rosenstock J, Durán-Garcia S, et al. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a 52-week randomized, double-blind study. Diabetes Care. 2013;36:3875-3881.
16. Otsuka Y, Yamaguchi S, Furukawa A, et al. Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes. Endocr J. 2015;62:133-143.
17. Sato S, Saisho Y, Kou K, et al. Efficacy and safety of sitagliptin added to insulin in Japanese patients with type 2 diabetes: the EDIT randomized trial. PLoS One. 2015;10(3):e0121988.
18. Mathieu C, Shankar RR, Lorber D, et al. A randomized clinical trial to evaluate the efficacy and safety of coadministration of sitagliptin with intensively titrated insulin glargine. Diabetes Ther. 2015;6(2):127-142.
19. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262-274.
20. Mudaliar S, Henry RR, Boden G, et al. Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin. Diabetes Technol Ther. 2014;16(3):137-144.
21. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509-514.
22. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose co-transporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499-508.
23. Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015;12 (2):90-100.
24. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. NEJM. 2015;373:2117-2128. DOI:10.1056/NEJMoa1504720. [Epub ahead of print].
25. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [Internet]. The Cochrane Collaboration; 2011 [updated 2011 Mar; cited 2015 Oct 1]. Available from: http://www.cochrane-handbook.org
26. Wilding JP, Norwood P, T'joen C, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32:1656-1662.
27. Wilding JP, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin. Ann Intern Med. 2012;156:405-415.
28. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diab Obes Metab. 2012;14(6):539-545.
29. Dumas R, Davies M, Rosenstock J, et al. Effects of canagliflozin added on to basal insulin other antihyperglycemic agents in type 2 diabetes. Can J Diabetes. 2013;37: S13-S84. Abstract 73.
30. Wilding JP, Woo V, Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2014;16(2):124-136.
31. van Haalen HG, Pompen M, Bergenheim K, et al. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands. Clin Drug Investig. 2014;34(2):135-146.
32. Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37(7):1815-1823.
33. Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38 (3):403-411.
34. Rosenstock J, Jelaska A, Zeller C, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015;17(10):936-948.
35. Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type2 diabetes: a preliminary report. Diabetes Care. 2004;27:17-20.
36. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care. 2001;24:758-767.
37. Carver C. Insulin treatment and the problem of weight gain in type 2 diabetes. Diabetes Educ. 2006;32:910-917.
38. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes-causes,effects and coping strategies. Diabetes Obes Metab. 2007;9:799-812.
39. UK Prospective Diabetes Study (UKPDS) 34 Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-865.
40. McAdam-Marx C, Mukherjee J, Bellows BK, et al. Evaluation of the relationship between weight change and glycemic control after initiation of antidiabetic therapy in patients with type 2 diabetes using electronic medical record data. Diabetes Res Cin Pract. 2014;103(3):402-411.